Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boston Therapeutics has commenced its first clinical trial to assess the efficacy and safety of PAZ320 in patients with Type 2 Diabetes Mellitus, when added to oral agents or Insulin regimen.
Subscribe to our email newsletter
PAZ320 is a chewable complex carbohydrate-based compound designed to reduce post-meal elevation of blood glucose, as it blocks the action of carbohydrate-hydrolyzing enzymes.
The trial will comprise adults aged 18-75 years with Type 2 diabetes, either on oral agents or insulin with a BMI of 25-35 kg/m2 and with A1c of less than 9.0%.
Boston Therapeutics CEO Sushela Chaidarun said PAZ320 has shown significant reduction of post-meal elevation of glucose in preclinical models.